Premium
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months
Author(s) -
Duniva Inusa Baba Psalm,
Inati Adlette,
Maes Philip,
Githanga Jessie,
Ogutu Bernhards,
Abboud Miguel R.,
Miano Maurizio,
Cela Elena,
Nduba Videlis,
Niazi Mohammad,
Åstrand Magnus,
Persson Kevin,
Berggren Anders,
Carlson Glenn
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28977
Subject(s) - ticagrelor , medicine , pharmacokinetics , pharmacology , anesthesia , clopidogrel , myocardial infarction
Inhibition of platelet activation may reduce vaso‐occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR‐C124910XX) exposure were comparable across all groups (<6 months, ≥6 to <12 months and ≥12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD.